JPRN-UMIN000028130已完成未知
Special Drug-Use Results Survey of IMBRUVICA Capsules 140 mg (relapsed or refractory mantle cell lymphoma [MCL]) - Special Drug-Use Results Survey of IMBRUVICA Capsules 140 mg (relapsed or refractory mantle cell lymphoma [MCL])
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Special Drug Use-Results Survey for IMBRUVICA Capsules 140 mgRelapsed or refractory chronic lymphocytic leukemia, including patients with small lymphocytic lymphomaJPRN-UMIN000021963Janssen Pharmaceutical K.K.200
已完成
Unknown
Special Drug Use-Results Survey of ParsabivSecondary hyperparathyroidism on hemodidalysisJPRN-jRCT1080224015ONO PHARMACEUTICAL CO.,LTD.1,200
招募中
不适用
General drug use-results survey of UPASITA IV Injection Syringe for DialysisJPRN-jRCT2041210113Dept. Pharmacovigilance770
已完成
Unknown
Special Drug Use-Results Survey of Onoacttachyarrhythmia, atrial fibrillation/atrial flutter in patients with cardiac dysfunctionJPRN-jRCT1080222572ONO PHARMACEUTICAL CO., LTD.800
进行中（未招募）
Unknown
Post-marketing Surveillance Protocol Number; CRTH258B1401diabetic macular edema (DME)JPRN-jRCT2031220323Sugimoto Toshiya200